Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | GABRP | O00591 | 2/20 | 0.30 |
| ▸ | GABRD | O14764 | 2/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.30 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.30 |
| ▸ | GABRE | P78334 | 2/20 | 0.30 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.30 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.30 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.30 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21056135 | 0.83 | — | — | |
| SCHEMBL27791955 | 0.82 | — | — | |
| SCHEMBL28071786 | 0.82 | — | — | |
| SCHEMBL1843724 | 0.81 | — | — | |
| SCHEMBL2556471 | 0.81 | OPRM1 (0.37) | OPRM1TP53GABRPGABRDGABRA1 | |
| SCHEMBL11186806 | 0.80 | — | — | |
| SCHEMBL1606773 | 0.80 | — | — | |
| SCHEMBL375455 | 0.79 | — | — | |
| SCHEMBL732360 | 0.79 | — | — | |
| SCHEMBL587426 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 467 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103172830-A | Method for modifying acrylic ester by using organic silicon | UNIV HUAINAN UNION | 2013-06-26 | — | — | CN | claimed |
| US-7541123-B2 | Imaging member | XEROX CORPORATION (US) | 2009-06-02 | — | — | US | claimed |
| US-20060284194-A1 | Imaging member | XEROX CORPORATION | 2006-12-21 | — | — | US | claimed |
| CN-1478801-A | Method of modifying acrylate using organic silicone | 中国科学院广州化学研究所 | 2004-03-03 | — | — | CN | claimed |
| US-12570899-B2 | Bright silver based quaternary nanostructures | SHOEI CHEMICAL INC. (JP) | 2026-03-10 | — | — | US | disclosed |
| US-20240263069-A1 | BRIGHT SILVER BASED QUATERNARY NANOSTRUCTURES | SHOEI CHEMICAL INC. (JP) | 2024-08-08 | — | — | US | disclosed |
| US-11970646-B2 | Bright silver based quaternary nanostructures | SHOEI CHEMICAL INC. (JP) | 2024-04-30 | — | — | US | disclosed |
| EP-3816247-B1 | CURING MIXTURE | EVONIK OPERATIONS GMBH (DE) | 2022-12-07 | — | — | EP | disclosed |
| US-20220228057-A1 | BRIGHT SILVER BASED QUATERNARY NANOSTRUCTURES | NANOSYS, INC. (US) | 2022-07-21 | — | — | US | disclosed |
| US-11254819-B2 | Curing agent mixture | EVONIK OPERATIONS GMBH (DE) | 2022-02-22 | — | — | US | disclosed |
| EP-2994495-B2 | CROSSLINKING OF IPMS ADDUCTS AND AMINOSILANES | EVONIK OPERATIONS GMBH (DE) | 2021-09-22 | — | — | EP | disclosed |
| EP-3816247-A1 | CURING MIXTURE | Evonik Operations GmbH (DE) | 2021-05-05 | — | — | EP | disclosed |
| EP-0289216-A2 | Electrophotographic imaging member | XEROX CORPORATION (US) | 1988-11-02 | — | — | EP | disclosed |
| US-4780385-A | GREATER RESISTANCE TO FORMATION OF CHARGE DEFICIENT SPOTS | XEROX CORPORATION (US) | 1988-10-25 | — | — | US | disclosed |
| EP-0149914-B1 | OVERCOATED ELECTROPHOTOGRAPHIC IMAGING MEMBER | XEROX CORPORATION (US) | 1988-08-10 | — | — | EP | disclosed |
| US-4588667-A | Electrophotographic imaging member and process comprising sputtering titanium on substrate | XEROX CORPORATION (US) | 1986-05-13 | — | — | US | disclosed |
| EP-0161933-A2 | Electrophotographic imaging | XEROX CORPORATION (US) | 1985-11-21 | — | — | EP | disclosed |
| EP-0149914-A1 | Overcoated electrophotographic imaging member | XEROX CORPORATION (US) | 1985-07-31 | — | — | EP | disclosed |
| US-4515882-A | CHARGE TRANSFER COMPOUNDS AND CHARGE INJECTION ENABLING PARTICLES | XEROX CORPORATION (US) | 1985-05-07 | — | — | US | disclosed |
| US-4291110-A | ELECTROGRAPHY | XEROX CORPORATION (US) | 1981-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570899-B2 | Bright silver based quaternary nanostructures | LGALS3, ANXA3, ATXN2L | OPRM1 2012/4885TP53 286/4885GABRP 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.